Clinical Trials Browser

Terminated × INDUSTRY × SNX-5422 × Clear all

NCT02973399 2019-02-22

Efficacy and Safety of SNX-5422 Added to an Established Dose of Ibrutinib in CLL

Phase 1 Terminated

LymphoidOther hematologic neoplasm

Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02612285 2018-11-14

Study of SNX-5422 in TP53 Null Cancers

Phase 2 Terminated

1 enrolled 3 charts

Neoplasms

NCT01848756 2017-02-09

Safety and Efficacy of SNX-5422 in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Cancers

Phase 1/2 Terminated

15 enrolled 10 charts

Neoplasms